[Desopimon in the treatment of obesity].
The authors tested the tolerance and therapeutic effect of desopimon preparation (1-p-chlorophenyl-2-aminopropane hydrochloride) in 44 subjects with obesity--I, II and III degree. They found a manifested appetite-inhibiting effect of the medicament in 41 of the patients and slight in two (the treatment was discontinued in a female, due to urticaria). Side effects, similar to those described with phenformin and phenmethrazin derivatives were not established. Body-weight loss is 12,9 kg per subject for a period of a month and a half, and the analysis of the data revealed that the weight loss was entirely on the account of the fatty tissue reduction. Triglyceride diminution was established in serum whereas free fatty acids were increased. After the confrontation of their own data those of some other researchers, the authors recommend desopimon as a suitable additive means in the treatment of simple nutritive (hyperphagic) obesity.
D000328:Adult; D001067:Appetite Depressants; D002745:Chlorphentermine / Q000009:adverse effects / Q000627:therapeutic use*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000188:drug therapy*; D010645:Phentermine / Q000031:analogs & derivatives*; D014280:Triglycerides / Q000097:blood; D014581:Urticaria / Q000209:etiology
D001067:Appetite Depressants; D005230:Fatty Acids, Nonesterified; D014280:Triglycerides; D010645:Phentermine; D002745:Chlorphentermine
Preparatut dezopimon v lechenieto na zatulstvaneto